India's Central Drugs Standard Control Organisation (CDSCO) has stated that injectable cosmetic products are not permitted under law, closing off any ambiguity that formulators, importers and clinic chains may have relied on to market these treatments.

The declaration from the country's apex drug regulator carries direct compliance weight. Products administered by injection fall within the definition of drugs under Indian law, and the CDSCO position means they cannot be sold or promoted as cosmetics regardless of their intended aesthetic purpose.

What does the ruling change for the industry?

For brand owners, the statement hardens a boundary that had operated largely through interpretation. Injectable aesthetic products — dermal fillers, skin boosters, biostimulators and comparable injectables marketed on cosmetic claims — now sit squarely outside the legal cosmetics category in India.

The practical consequences spread across several functions:

• Product development and registration: any pipeline item delivered by injection must be assessed as a drug, not reformulated or labelled into the cosmetics lane.
• Import and distribution: importers of injectable aesthetic products face scrutiny under drug import controls rather than cosmetic notification procedures.
• Clinic menus: aesthetic chains and dermatology practices offering injectable treatments must verify that the products they use hold valid drug approvals.
• Marketing claims: promotional material describing injectables as cosmetics carries regulatory risk following the CDSCO statement.

Why the route to market matters

India's cosmetics framework does not provide an approval pathway for injectable presentations. A cosmetic product, however sophisticated its ingredient list or claim set, cannot legally cross into injectable format. Companies that treated injectables as a premium extension of a cosmetic portfolio now face a structural bar rather than a labelling question.

The regulator's public position also shifts enforcement expectations. When a national drug authority states on record that a product category is not permitted, state licensing authorities and customs officials gain a clear reference point for action against non-compliant stock and advertising.

What should compliance teams do now?

Professionals buying or formulating for the Indian market should audit their portfolios for any injectable-presented items marketed with cosmetic positioning. Each such product needs either a valid drug licence and approval status or removal from the Indian market plan.

Clinics and distributors should confirm that every injectable on their procurement list traces to an approved drug source, with documentation ready for inspection. The CDSCO statement gives inspectors a simple test: if it is injected and marketed for cosmetic outcomes without drug approval, it is out of bounds.

Watch for follow-up enforcement notices, state-level raids or import alerts in the coming months — the next concrete data point will be whether CDSCO couples its declaration with named product actions or a formal ban notification.